TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00794326

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Solution for Peritoneal Dialysis
Description: Treatment with one bag per day during 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solution for Peritoneal Dialysis
Description: Treatment with one bag per day during 6 months
Study: NCT04214951

Intervention type: DRUG
Intervention: Eltrombopag
Description: Patients will be given eltrombopag 50mg once daily for 6 weeks.
Study: NCT04023695

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid with lidocaine with epinephrine
Description: Trigger finger injection
Study: NCT04214951

Intervention type: DRUG
Intervention: Recombinant human thrombopoietin (rh-TPO)
Description: Patients will be given rh-TPO 300 U/kg once daily for 21 days.
Study: NCT00443352

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: duloxetine
Description: Duloxetine: 120 mg. daily or maximum tolerated dose (minimum: 60 mg per day)
Study: NCT03492073

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotional Supportive Mindfulness-based Program
Description: Mindfulness training

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Emotional Supportive Program
Description: Narrative-orientated therapy.
Study: NCT04777773

Intervention type: OTHER
Group type: OTHER
Intervention: dual-task training
Description: dual-task training

Intervention type: OTHER
Group type: OTHER
Intervention: dual-task training
Description: dual-task training
Study: NCT01986842

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein diet
Description: Subjects will receive either a low protein or a high protein diet for 14 days. High protein will be realized with protein supplements.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein diet
Description: Subjects will receive either a low protein or a high protein diet for 14 days. High protein will be realized with protein supplements.
Study: NCT01093859

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRX-105
Description: Sterile solution for intravenous injection
Study: NCT03754816

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PECS II and parasternal block
Description: 10 ml of Levobupivacaine 0.375% injected between minor and major pectoralis muscles. 20 ml of Levobupivacaine 0.375% injected between minor and serratus muscles. 10 ml of Levobupivacaine 0.375% injected between major and intercostal muscles at II and IV intercostal space.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levobupivacaine
Description: Levobupivacaine
Study: NCT03492983

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Intervention group
Description: 10 g/day of high cocoa content chocolate for six months.
Study: NCT04111237

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Two Finger technique
Description: two finger method for chest compression provuision

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Two Thumb Technique
Description: Two thumb technique
Study: NCT00545233

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: peginterferon alfa-2a [Pegasys]
Description: 180 micrograms subcutaneous weekly for 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a [Pegasys]
Description: 180 micrograms subcutaneous weekly for 48 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ribavirin [Copegus]
Description: 1000-1600 mg day orally for 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin [Copegus]
Description: 1000-1600 mg day orally for 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: 30 mg daily for 8 weeks increasing to 45 mg daily for 64 weeks.
Study: NCT01075620

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PFC-Sigma RP
Description: Posterior stabilizing rotating platform total knee components

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LPS RP
Description: non-posterior stabilized rotating platform design
Study: NCT00728559

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bupivacain 0.5%
Description: trocar site injection
Study: NCT05086705

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT04023695

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroid with normal saline
Description: Trigger finger injection
Study: NCT03019211

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Study: NCT06388525

Intervention type: PROCEDURE
Intervention: Endoscopic Retrograde Cholangiopancreatography
Study: NCT03675022

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: The investigational drug is dupilumab, 300mg in 2ml solution for subcutaneous application. All Patients will receive dupilumab, 300mg, every two weeks (8 subcutaneous injections total).
Study: NCT01726192

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Placement of a femoral catheter with the hydrolocalization technique
Description: Placement of femoral nerve catheter with the hydrolocalization technique, using ropivacaine 0.6%

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Placement of a femoral neurostimulating catheter
Study: NCT01923727

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: [89Zr]Df-IAB2M
Description: A single intravenous infusion of 5 mCi of \[89Zr\]Df-IAB2M in a mass dose of 10 mg, 20mg or 50mg.
Study: NCT02049073

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zonisamide
Description: Zonisamide 100 mg or 200 mg pill administered orally every day for 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Methylprednisolone 32 mg or 64 mg pill administered orally once
Study: NCT02628054

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Typhoid Vaccine
Description: Typhoid Vaccine injection given 7 days apart

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline injection given 7 days apart
Study: NCT01422889

Intervention type: DEVICE
Intervention: ION™ Coronary Stent System
Description: This study is intended to evaluate the ION™ Paclitaxel-Eluting Platinum Chromium Coronary Stent System across a range of institutions and physician users to observe and assess subject outcomes and technology performance in a real-world setting.
Study: NCT03859596

Intervention type: PROCEDURE
Intervention: MGB/OAGB
Description: BARIATRIC PROCEDURE INVOLVED CREATION OF SLENDER GASTRIC POUCH OF 12-15CM IN LENGTH AND BILIO-PANCREATIC LIMB OF 150-200 CM
Study: NCT01591135

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel plus 5-fluorouracil
Description: 5-ﬂuorouracil 300 mg/m2, d1-4, continuous infusion for 96 hours and paclitaxel 50 mg/m2 over 3 hours, d1 (week 1, week 2, week 3, week 4 and week 5); 5-ﬂuorouracil 600 mg/m2/d d1-3 and paclitaxel 175 mg/m2 d1(week 9 and week 13).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin plus 5-fluorouracil
Description: cisplatin 25 mg/m2/d, d1-3, once every 4 weeks for 4 cycles (week 1, week 5, week 9 and week 13); 5-FU 600 mg/m2/d, d1-3, continuously infusion for 72 hrs,once every 4 weeks for 4 cycles (week 1, week 5, week 9 and week 13).

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation therapy
Description: A total dose of 61.2 Gy will be delivered in 34 fractions at 1.8 Gy/fraction, 5 fractions per week in 6.8 weeks.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: A total dose of 61.2 Gy will be delivered in 34 fractions at 1.8 Gy/fraction, 5 fractions per week in 6.8 weeks.
Study: NCT00664768

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Neocate Infant
Description: minimum of 8 fl. oz daily

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: new Neocate
Description: minimum of 8 fl oz daily
Study: NCT00916084

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fixed Tongue Appliance
Description: A functional appliance used for maxillary protraction. It has two bands on first molars, expansion screw and long palatal plate in the canine area which cages the tongue and transfers the force of the tongue during physiological activity to the upper arch.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fixed Face Mask
Description: An extra-oral appliance used for treatment of maxillary deficiency in growing patients. It takes anchorage from the chin and forehead, has a fixed intra-oral appliance with an expansion screw and hooks for elastics that exert a force of 300 gr. It should be used 14 hours a day.
Study: NCT01747616

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Chitosan-N-acetylcysteine eye drops (concentration of 0.1%)
Description: 1 drop of the medical device in 1 randomly chosen eye

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Chitosan-N-acetylcysteine eye drops (concentration of 0.1%)
Description: 1 drop of the medical device in 1 randomly chosen eye

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiological saline solution
Description: 1 drop as placebo in the other eye not receiving the medical device

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiological saline solution
Description: 1 drop as placebo in the other eye not receiving the medical device

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiological saline solution
Description: 1 drop as placebo in the other eye not receiving the medical device

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiological saline solution
Description: 1 drop as placebo in the other eye not receiving the medical device
Study: NCT03035149

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Weight Management Program
Description: Obese subjects partake in a medically supervised weight management program. This lifestyle modification program involves weekly three hour sessions for six months and monthly sessions for six months. The first twelve weeks comprise an initial weight loss phase when patients are placed on a 900 Kcal/day meal replacement. This is followed by a four week transition to a 1200-1800 Kcal diet followed by a ten week maintenance phase of 10 weekly sessions.The majority of weight loss occurs during the first 26 weeks followed by a 26 week period of stabilization of weight loss. Hence subjects are evaluated after the first 26 weeks.
Study: NCT00669149

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clopidogrel + aspirin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: heparin + clopidogrel + aspirin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: enoxaparin + clopidogrel + aspirin
Study: NCT01907490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ha44 Gel
Description: Eligible subjects will be treated at the study site on Day 0 with a single application of the maximum feasible amount of Ha44 Gel, to ensure saturation of the scalp and hair.
Study: NCT03142139

Intervention type: BIOLOGICAL
Intervention: RQ1a: Delayed vs. timely vaccination with the 1st dose of DTaP-IPV-Hib
Description: Children will be categorized as timely vaccinated if they receive the 1st dose within the month of scheduled vaccination:~* timely vaccinated: received 1st dose of DTaP-IPV-Hib before 4 months of age~* delayed vaccinated: did not receive the first dose of DTaP-IPV-Hib before 4 months of age.

Intervention type: BIOLOGICAL
Intervention: RQ1b: Delayed vs. timely vaccination with the 2nd dose of DTaP-IPV-Hib
Description: Children will be categorized as timely vaccinated if they receive the 2nd dose within the month of scheduled vaccination:~* timely vaccinated: received 2nd dose of DTaP-IPV-Hib before 6 months of age~* delayed vaccinated: did not receive the 2nd dose of DTaP-IPV-Hib before 6 months of age.

Intervention type: BIOLOGICAL
Intervention: RQ2: Vaccination with DTaP-IPV-Hib compared to being unvaccinated
Description: • Vaccination status will be assessed as a time dependent exposure, whereby children will be categorized as unvaccinated until date of vaccination where they will shift exposure group to vaccinated.
Study: NCT05386459

Intervention type: DRUG
Intervention: Interferon Gamma
Description: injection form
Study: NCT02560922

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pain Coping Skills Training (CST)
Description: The pain CST intervention includes 11 individual sessions with a study counselor, delivered via telephone to enhance access and reach. The sessions include the following: general information about why pain coping skills training is important, training in specific pain coping skills (such as progressive muscle relaxation, communication, imagery, and activity pacing), and guided practice with each skill. The CST program will also include information about other behaviors important for OA, such as physical activity and weight management.
Study: NCT02183324

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose of BI 1356 BS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medium dose of BI 1356 BS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose of BI 1356 BS

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02097472

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PATH-wSP
Description: Streptococcus pneumoniae Whole Cell Vaccine adsorbed to Alum

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PATH-wSP
Description: Streptococcus pneumoniae Whole Cell Vaccine adsorbed to Alum
Study: NCT01844804

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-06438179
Description: Single-dose of 10 mg/kg administered as an intravenous infusion in not less than 2 hours on Day 1

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Remicade
Description: Single-dose of 10 mg/kg administered as an intravenous infusion in not less than 2 hours on Day 1
Study: NCT00249457

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency management
Description: Invited to attend the Therapeutic Workplace 3 hr per day, Monday through Friday. Each day when a participant reported to the workplace, she was required to provide a urine sample. If the sample tested negative for opiates and cocaine, she was allowed to work that day. Participants who gained entrance to the workplace participated in basic skills education and job skills training throughout each 3-hr work shift.
Study: NCT02801448

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sulforaphane
Description: sulforaphane-containing broccoli sprout extracts

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Maltodextrine-based placebo without sulforaphane
Study: NCT00194818

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Asacol (mesalamine)
Description: Available in 400mg delayed release tablet. Randomized to either 6 tablets BID (4.8 g/day) or 4 tablets TID (4.8 g/day) for a total of 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Asacol (mesalamine)
Description: Available in 400mg delayed release tablet. Randomized to either 6 tablets BID (4.8 g/day) or 4 tablets TID (4.8 g/day) for a total of 12 weeks.
Study: NCT00580359

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S-1, capecitabine
Description: S-1 40mg/m2 orally twice daily on days 1(evening) - 15 (morning)every 3 weeks, until disease progression, Capecitabine 1250mg/m2 orally twice daily on days 1 (evening) - 15 (morning)every 3 weeks, until disease progression

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S-1, capecitabine
Description: S-1 40mg/m2 orally twice daily on days 1(evening) - 15 (morning)every 3 weeks, until disease progression, Capecitabine 1250mg/m2 orally twice daily on days 1 (evening) - 15 (morning)every 3 weeks, until disease progression
Study: NCT01102777

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: automated internet-mediated walking program
Description: intervention participants are encouraged to walk daily to their step-count goal while wearing a pedometer provided by the study that will measure their daily step-counts. They are also encouraged to log into their personally tailored website to upload their step counts and obtain other information about the study and progress

Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: Control group, instructed to wear the pedometer but not provided with walking goals or instruction.
Study: NCT01121900

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trazodone HCl
Description: Dosage form: Extended-release caplets containing 300 mg trazodone HCl~Dose: 300 mg trazodone HCl extended-release caplets (one caplet) at 23:30 on Day 1 of the test product treatment period following a fasting period of at least 4 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trazodone HCl
Description: Dosage form: Immediate-release tablets containing 100 mg trazodone HCl~Dose: 100 mg trazodone HCl immediate-release tablets (one tablet per dosing time) at 23:30 on Day 1, at 07:30 and 15:30 on Day 2 of the reference product treatment period.
Study: NCT03601247

Intervention type: DEVICE
Group type: OTHER
Intervention: silicone gel
Description: Patients who have consented to the study will receive two tubes labeled only left and right, corresponding to the side of the face to which the tube contents will be applied. One tube will contain silicone gel and the other tube will contain aquaphor. Neither the patient nor the surgeon will know what side will receive which treatment. These tubes will be given to patients at post-operative week 1 visit. Patients will be instructed to rub the solution into their eyelid incisions gently with their fingers for 2-3 minutes twice a day
Study: NCT00162435

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Study: NCT03440281

Intervention type: DIAGNOSTIC_TEST
Intervention: Uterine artery doppler
Description: Uterine artery Doppler pulsatility indices

Intervention type: DIAGNOSTIC_TEST
Intervention: Uterine artery doppler
Description: Uterine artery Doppler pulsatility indices

Intervention type: DIAGNOSTIC_TEST
Intervention: Maternal serum homocysteine estimation
Study: NCT01844804

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Remicade
Description: Single-dose of 10 mg/kg administered as an intravenous infusion in not less than 2 hours on Day 1
Study: NCT00485485

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib Mesylate
Description: 400 mg by mouth daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 60 mg/m\^2 by vein (IV) over 1 hour every 3 weeks
Study: NCT05853250

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reiki/manual therapy
Description: Reiki is delivered by gentle hand placement either on or slightly above the body by certified Reiki practitioners. In this study, Reiki will be delivered first, for 15 minutes and will involve light placement of hands on patients' head, chest, shoulders, hands, knees, and feet (\~ 3 minutes to each body part). Manual therapy techniques include light effleurage to head and feet (for 5 minutes; \~ 2.5 minutes to each body part) by the Reiki practitioner who delivered the Reiki therapy.
Study: NCT04137380

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirikizumab - IV
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirikizumab - SC
Description: Administered SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - IV
Description: Administered IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - SC
Description: Administered SC
Study: NCT03440281

Intervention type: DIAGNOSTIC_TEST
Intervention: Maternal serum homocysteine estimation
Study: NCT01802346

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: dietary intervention
Description: Consume a low-calorie diet

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: nutritional support
Description: Receive dietary advice

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT02724137

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fitbit®
Description: Participants can read how many steps/day they walked on the Fitbit® daily. The treating physical therapist reviews Fitbit® recorded steps from the previous week and together with the patient sets a new step goal. The physical therapist discusses barriers to meeting step goals are discussed. Self-reward for meeting step/goal is set weekly. Participants in this group will also receive 1-month phone calls for 6-months after completing physical therapy rehabilitation to discuss physical activity, set monthly step count goal, barriers to overcoming goal and to continue to develop a reward system for when the participant achieves their step count goal.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy Rehab
Description: Standard of care physical therapy after total knee replacement. The goals of physical therapy are to increase knee range of motion and strength, improve balance and agility, and increase daily walking. Physical therapy appointment times range from 45-60 minutes with appointments occurring 2 times a week for 6-8 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Therapy Rehab
Description: Standard of care physical therapy after total knee replacement. The goals of physical therapy are to increase knee range of motion and strength, improve balance and agility, and increase daily walking. Physical therapy appointment times range from 45-60 minutes with appointments occurring 2 times a week for 6-8 weeks.
Study: NCT01872689

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lebrikizumab
Description: Lebrikizumab will be administered at a dose of 250 mg via SC injection once every 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lebrikizumab
Description: Lebrikizumab will be administered at a dose of 250 mg via SC injection once every 4 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lebrikizumab
Description: Lebrikizumab will be administered at a dose of 250 mg via SC injection once every 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirfenidone
Description: Pirfenidone will be administered orally at a stable dose of 2403 mg per day or at MTD.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pirfenidone
Description: Pirfenidone will be administered orally at a stable dose of 2403 mg per day or at MTD.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched to lebrikizumab will be administered via SC injection once every 4 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched to lebrikizumab will be administered via SC injection once every 4 weeks.